Skip to main content
SpringerLink
Log in

Clinical Trials with Local Administration of Lymphopoietic Growth Factors

  • Conference paper
Lymphohaematopoietic Growth Factors in Cancer Therapy II

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

A large body of data emerging both from in vitro tests and experimental animal models shows that interleukins (ILs) regulate the induction of many functions of an immune response by acting as the elements of a cell-cell communication code. Moreover, the experimental addition of ILs amplifies many immune reaction mechanisms both in vitro and in vivo [1]. Efforts have, therefore, been made to use ILs to modulate immune responses. This approach has been rendered easier by recombinant DNA technology, which has made several ILs available in unlimited amounts.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Forni G, Fujiwara H, Martino F, Hamakoa T, Jemma C, Carette P, Giovarelli M: Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunoterapy. Cancer Metast Rev 1988 (7):289–308

    Google Scholar 

  2. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White JP: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. New Engl J Med 1988 (319):1676–1680

    Google Scholar 

  3. Forni G, Giovarelli M, Jemma C, Bosco MC, Caretto P, Modesti A, Santoni A, Forni M, Cortesina G, De Stefani A, Cavallo GP, Galeazzi E, Musiani P, De Campora E, Valitutti S, Castellino F, Calearo CV, Fontana G, Sesia G: Perilymphatic injections of cytokines: A new tool in active cancer immunotherapy. Experimental rationale and clinical findings. Ann 1st Super Sanità 1990 (26):397–410

    Google Scholar 

  4. Belardelli F, Proietti E, Ciolli V, Sestili P, Carpinelli G, Di Vito M, Ferretti A, Woodrow D, Boraschi D, Podo F: lnterleukin-16 induces tumor necrosis and early morphologic and metabolic changes in transplantable tumors. Similitaries with the anti-tumor effects of tumor necrosis factor alpha or beta. Int J Cancer 1989 (44):116–121

    Google Scholar 

  5. Jemma C, Giovarelli M, Faltynek CR, Benetton G, Forni M, Caretto P, Brunda M, Varesio L, Geuna M, Forni G: Human interferon gamma stimulates a human T-cell lymphoma to proliferate in vitro but inhibits its oncogenicity in immunosuppressed nude mice. J Immunol Res 1989 (1):111–119

    Google Scholar 

  6. Edwards L, Whiting D, Rogers D, Luck K, Smiles KA: The effect of intralesional IFN gamma on basal cell carcinomas. J Am Acad Dermatol 1990 (22):496–500

    Google Scholar 

  7. Spirtos NM, Smith LH, Teng NN: Prospective randomized trial of topical alpha-IFN (alpha-IFN gels) for the treatment of vulvar intraepithelial neoplasia III. Gynecol Oncol 1990 (37):34–8

    Google Scholar 

  8. von Wussow P, Block B, Hartmann F, Deicher H: Intralesional IFN-alpha therapy in advanced malignant melanoma. Cancer 1988 (61):1071–1074

    Google Scholar 

  9. Irie K, Satonaka K, Matsuura M, Miura Y, Nakayama H: A case of vulva cancer responding to the recombinant human tumor necrosis factor (PT-950) local injection therapy. Gan No Rinsho 1988 (34):946–950

    Google Scholar 

  10. Huland E, Huland H, Heinzer H: Inhalative interleukin-2 application: an efficient and nontoxic topical treatment of pulmonary metastases. 7 Cong Soc Ital Immunofarmacol, Stresa 1991:50 (abstract)

    Google Scholar 

  11. Lienard D, Lejeune F, Ewalenco P: High doses of rTNF-alpha, rIFN-gamma and melphalan administered in isolation perfusion produce 89% of complete remission in melanoma and sarcoma. Cytokine 1991 (3):491 (abstract)

    Google Scholar 

  12. Eggermont AMM, Goey S, Bolhuis RLH, Lejeune F, Stoter G: Experience with various clinical protocols for regional immunotherapy with cytokines. 7 Cong Soc Ital Immunofarmacol, Stresa 1991:53 (abstract)

    Google Scholar 

  13. Rambaldi A, Introna M, Colotta F, Landolfo S, Colombo N, Mangioni C, Mantovani A: Intraperitoneal administration of IFN beta in ovarian cancer patients. Cancer 1985 (56):294–301

    Google Scholar 

  14. Berek JS, Hacker NF, Lichtenstein A: Intraperitoneal recombinant alpha-IFN for “savage” immunotherapy in stage III epithelial ovarian cancer: a gynecologic oncology group study. Cancer Res 1985 (45):4447–4453

    Google Scholar 

  15. Bezwoda W, Seymour L, Dansey R: Intraperitoneal recombinant IFN-alpha 2b for recurrent malignant ascites due to ovarian cancer. Cancer 1989 (64):1029–1033

    Article  PubMed  CAS  Google Scholar 

  16. Willemse PH, de Vries EG, Mulder NH, Aalders JG, Bouma J, Sleijfer DT: Intraperitoneal human recombinant IFN alpha-2b in minimal residual ovarian cancer. Eur J Cancer 1990 (26):353–358

    Article  PubMed  CAS  Google Scholar 

  17. Lotze MT, Custer MC, Rosenberg SA: Intraperitoneal administration of interleukin-2 in patients with cancer. Arch Surg 1986 (121):1373–1379

    Google Scholar 

  18. Stewart JA, Belison J, Moore A, Dorighi J, Grant B, Haugh L, Roberts,J, Albertini R, Branda R: Phase I trial of intraperitoneal recombinant interleukin- 2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 1990(50):6302–6310

    PubMed  CAS  Google Scholar 

  19. Chapman P, Kolitz J, Hakes T, Gabrilove J, Welte K, Merluzzi V, Engert A, Bradley E, Konrad M, Mertelsman R: A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma. Invest New Drugs 1988 (6):179–188

    Article  PubMed  CAS  Google Scholar 

  20. Mantovani A: Attività antitumorale e immunomodulante dell’interferon intraperitoneale in pazienti con carcinoma ovarico con malattia residua minima dopo chemioterapia. 7 Cong Soc Ital Immunofarmacol, Stresa 1991:52 (abstract)

    Google Scholar 

  21. Melioli G, Baldini E, Mingari MC, De Maria A, Sertoli R, Badellino F, Percivale PL, Catturich A, Bertoglio S, Civalleri D, Santi L, Moretta L: Phenotypic and funcional characteristics of tumor-associated lymphocytes in patients with malignant ascites receiving intraperitoneal infusions of recombinant interleukin-2 (rlL2). Int J Cancer 1989 (43):231–234

    Article  PubMed  CAS  Google Scholar 

  22. Yasumoto K, Miyazaki K, Nagashima A: Induction of lymphokine-activated killer cells by intra-pleural instillation of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 1987 (47):2184–2189

    Google Scholar 

  23. Thatcher N, Taylor P, Carroll KB, Loriaux EM, Palmer P, Franks CR: Interleukin-2 in malignant pleural mesothelioma (and adenocarcinoma of the lung). The use of intrapleural and continuous intravenous infusions: preliminary results. Cancer Treat Rev 1989 (16):161–162

    Google Scholar 

  24. Fateli MR, Housepian EM, Oster MW, Cote DN, Sisti MB, Marcus SG, Fisher PB: Intratumor administration of beta-IFN in recurrent malignant gliomas. A phase I clinical and laboratory study. Cancer 1990 (65):78–83

    Google Scholar 

  25. Blancher A, Roubinet F, Grancher AS, Calot JP, Ducos J, Remoulet M, Clanet M, Bonafé A, Rascol A, Pourreau CN, Palmer PA, Franks CR: Adoptive local immunotherapy of malignant glyomas In: E Lotzova, L Bergman (eds) Frankfurt International Interleukin Symposium, Karger, Berlin 1990 p 72

    Google Scholar 

  26. Yoshida S, Tanaka R, Ono K: Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res 1988 (48):5011–5016

    Google Scholar 

  27. Merchant R, Grant A, Merchant L, Young H: Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer and recombinant interleukin-2. Cancer 1988 (62):665–671

    Google Scholar 

  28. Cortesina G, Giovarelli M, Jemma C, De Stefani A, Forni G: Effect of low doses of interelukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinomas. J Biol Resp Modif 1989 (8):571–578

    Google Scholar 

  29. Saito T, Kakiuti H, Kuki K, Yokota M, Jinnin T, Kimura T, Fujiwara K, Yoda J, Kunimoto M, Arai H: Clinical evaluation of local administration of rlL-2 in head and neck cancer. Nippon Jibiinokoka Gakkai Kaiho 1988 (92):1265–1270

    Google Scholar 

  30. Musiani P, De Campora E, Valitutti S, Castellino F, Calearo CV, Cortesina G, Giovarelli M, Jemma C, De Stefani A, Forni G: Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma. J Biol Resp Modif 1989 (8):571–578

    Google Scholar 

  31. Saito T, Kawaguti Yoda J, Kimura T, Tabata T: Immunohistology of tumor tissues in local administration of recombinant IL-2 in head and neck cancer. Nippon Jibiinokoka Gakkai Kaiho 1989 (92):1271–1276

    Google Scholar 

  32. Valente G, De Stefani A, Jemma C, Giovarelli M, Geuna M, Cortesina G, Forni G, Palestro G: Infiltrating leukocyte population and T-lymphocyte subsets in head and neck squamous cell carcinomas from patients receiving perilymphatic injections of recombinant interleukin 2. Modern Pathol 1990 (6):702–708

    Google Scholar 

  33. Rivoltini L, Gambacorti-Passerini C, Squadrelli- Saraceno M, Grosso Ml, Cantù G, Molinari R, Orazi A, Parmiani G: In vivo interleukin-2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res 1991 (50):5551–5557

    Google Scholar 

  34. Sawaki S: A phase 2 study of recombinant interleukin-2 (S-6820) for head and neck cancer. Gan No Rinsho 1990 (36):111–120

    Google Scholar 

  35. Cortesina G, De Stefani A, Giovarelli M, Galeazzi E, Cavallo G P, Jemma C, Giovarelli M, Vai S, Forni G: Interleukin-2 injected around draining lymph nodes in head and neck cancer. Head and Neck 1991 (13):125–131

    Google Scholar 

  36. Okuno K, Tagagui H, Nakamura Y, Iwasa Z, Yasutomi M: Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine- activated killer cells generated from autologous spleen cells. Cancer 1986 (58):1001–1006

    Google Scholar 

  37. Fagan EA, Pulley M, Limb A, Wolstencroft R, Cranenburgh C, De Vinci C, Karani J, Micheli M, Nunnerley H, Zaman S, Pizza G, Dumonde D, Williams R: Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinoma. Cancer Treat Rev 1989 (16):151–160

    Google Scholar 

  38. Mavligit GM, Zukiwski AA, Gutterman JU, Salem P, Charnsangavej C, Wallace S: Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases. J Clin Oncol 1990 (8):319–324

    PubMed  CAS  Google Scholar 

  39. Eggermont A M, Goey S H, Wiggers T, Franks CR, Bolhuis R, Stoten G: Hepatic artery infusion with interleukin-2 in patients with unresectable colorectal hepatic metastatic disease: a phase IB study. In: E Lotzova, L Bergman (eds) Frankfurt International Interleukin Symposium, Karger, Berlin 1990 p 74

    Google Scholar 

  40. Chien C, Hsieh K, Yang P: Immunochemotherapy with recombinant interleukin-2 and adriamycin in primary hepatocellular carcinoma. Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih 1991 (24):201–212

    PubMed  CAS  Google Scholar 

  41. Shirai M, Watanabe S, Nishioka M: Antitumor effect of intratumoral injection of human recombinant interleukine-2 in patients with hepatocellular carcinoma: a preliminary report. Eur J Cancer 1990 (26):1045–1048

    Article  PubMed  CAS  Google Scholar 

  42. Onishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, Matsunaga Y, Yamamoto Y: Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma. Hepatology 1989 (10):349–353

    Google Scholar 

  43. Pizza G, Severini P, Mennini D, De Vinci C, Corrado F: Tumor regression after intralesional injection of interleukin-2 (IL-2) in bladder cancer. A preliminary report. Int J Cancer 1984 (34):539–367

    Google Scholar 

  44. Fujioka T: The efficacy of r interleukin 2 in local treatment of superficial bladder tumors. Hinyokika Kiyo 1988 (349):2115–2119

    Google Scholar 

  45. Huland E, Huland H: Local continuous high dose interleukin 2: a new therapeutic model for treatment of advanced bladder carcinoma. Cancer Res 1989 (49):5469–5474

    Google Scholar 

  46. Tubaro A, Velotti F, Stopacciaro A, Santoni A, Vicentini C, Bossola PC, Galassi P, Pettinato P, Morrone S, Napolitano T, Frati L, Ruco L, Franks CR, Palmer PA, Pourreau CN: Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin- 2. Cancer 1991 (68):56–61

    Google Scholar 

  47. Velotti F, Stopacciaro AL, Ruco L, Tubaro A, Santoni A, Vicentini C, Bossola PC, Galassi P, Pettinato P, Morrone S, Napolitano T, Frati L, Franks CR, Palmer PA, Pourreau CN: Continuous intraarterial administration of recombinant interleukin-2 in low-stage bladder cancer. A phase IB study. Cancer Res 1991 (51):2456–2462

    Google Scholar 

  48. Fontana G: IFN-gamma in the treatment of superficial and recurrent bladder carcinoma In: Therapeutic Progress in Urological Cancers. Alan R Liss Inc, New York 1989 pp 479–480

    Google Scholar 

  49. Kedar K, Klein E: Cancer immunotherapy: why are clinical results discouraging - can they be improved? Adv Cancer Res 1991 (in press)

    Google Scholar 

  50. Nanni P, De Giovanni C, Lollini PL, Nicoletti G, Prodi G: TS/A: a new metastasizing cell line originated from a BALB/c spontaneous mammary adenocarcinoma. Clin Expl Met 1983 (1):373–380

    Google Scholar 

  51. Forni G, Giovarelli M, Santoni A, Modesti A, Forni M: lnterleukin-2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. J Immunol 1987 (138):4033–4041

    Google Scholar 

  52. Bosco MC, Giovarelli M, Forni M, Modesti A, Scarpa S, Masuelli L, Forni G: Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J Immunol 1990 (145):3136–3143

    Google Scholar 

  53. Cortesina G, De Stefani A, Giovarelli M, Barioglio MG, Cavallo GP, Jemma C, Forni G: Treatment of recurrent squamous cell carcinoma of head and neck with low doses of interleukin-2 (IL-2) injected perilymphatically. Cancer 1988 (62):2482–2490

    Google Scholar 

  54. Mattijssen V, De Mulder PH, Shornagel HJ, Verweij J, Van den Broek P, Galazka A, Rpy S, Ruiter DJ: Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, non-pretreated head and neck squamous cell carcinomas. J Immunother 1991 (10):63–68

    Google Scholar 

  55. Mitchell SM: Combining chemotherapy with biological response modifiers in treatment of cancer. JNCI 1988 (80):1145–1150

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Microbiology, University of Turin, Italy

    Federica Pericle & Francesco Di Pierro

  2. Centre of Immunogenetics and Histocompatibility, via Santena 19, 10126, Turin, Italy

    Guido Forni

Authors
  1. Federica Pericle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Di Pierro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guido Forni
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung Innere Medizin I, Klinikum der Albert-Ludwigs-Universität, Hugstetter Straße 55, 7500, Freiburg, Federal Republic of Germany

    Roland Mertelsmann

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Pericle, F., Di Pierro, F., Forni, G. (1992). Clinical Trials with Local Administration of Lymphopoietic Growth Factors. In: Mertelsmann, R. (eds) Lymphohaematopoietic Growth Factors in Cancer Therapy II. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77801-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-77801-8_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-77803-2

  • Online ISBN: 978-3-642-77801-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation